Drug
Atogepant
Atogepant: highest development phase Phase 3, developed by AbbVie. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| Atogepant NCT05711394 | Phase 3 | Episodic Migraine |
Latest
No recent events.
Follow Atogepant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.